Research · Sep 3, 2026
Procter & Gamble FY2025 (June 2025) revenue ~$84.5B with adj. operating margin expanding to 24% (from 22.6% FY2022) on productivity savings + mix shift toward higher-margin Beauty (25%)/Grooming (30%)/Health Care (25%) segments. Organic sales growth +4-5% — moderating from +7% peak inflation pricing era as volume recovery resumes. FY2026 thesis: continued margin expansion toward 25-26% by FY2027 driven by Beauty/Grooming/Health Care growing 4-6% organically vs consolidated 4-5%; emerging market expansion (~30% of revenue at 6-8% organic growth) durable; key risks: private-label competitive intensity in Family Care (Bounty/Charmin/Puffs vs Walmart Equate / Costco Kirkland), currency translation headwind, US recession compressing discretionary categories.
Research · Apr 27, 2026
Procter & Gamble's fiscal Q3 results met Wall Street expectations, clearing tariff and margin fears that drove the March selloff. The stock is positioned for a 1-2% tactical move as the downside case is removed, but muted peer response signals limited sector read-through. The trade is a 30-day long in PG, fading if Q4 fails to show margin expansion or if broader market volatility exceeds 5%.
Research · Apr 13, 2026
Potential Strait of Hormuz blockade risks broad inflation, favoring pricing power staples like PG, COST, and WMT while pressuring discretionary TGT and input-heavy CAT/DE. Analysis ranks PG highest conviction amid TTM metrics showing superior margins and growth resilience.
Research · Apr 13, 2026
UMich economist flags stretched US consumers amid high prices, driving trade-down to discounters like WMT, COST, TGT while hurting NKE, SBUX. Staples PG holds steady. Ranked picks favor value plays with strong financials.
Research · Apr 10, 2026
Stagflation trades are gaining traction as inflation sticks and growth slows; energy giants XOM and CVX top the list for cash flow, followed by gold miner NEM, staples PG/COST, and utility NEE. Ranked conviction favors commodity producers with strong balance sheets.
